Murrell Donna H, Karnas Scott J, Corkum Mark T, Hipwell Scott, Palma David A, Rodrigues George, Louie Alexander V
Physics and Engineering, London Regional Cancer Program, London, ON, Canada.
Department of Radiation Oncology, London Health Sciences Centre, London, ON, Canada.
J Thorac Dis. 2019 May;11(5):2099-2104. doi: 10.21037/jtd.2019.05.40.
Radical thoracic radiotherapy is ideally delivered in the arms-up (AU) position; however, patient comfort may only allow for arms-down (AD) positioning to be feasible. Objectives of this study were (I) to evaluate the dosimetric impact of changing arm position during treatment and (II) to compare plan quality for optimization in AU AD positions. In this retrospective planning study, stage III lung cancer patients (n=10) who received 60 Gy in 30 fractions using volumetric modulated arc therapy (VMAT) were identified. To simulate AD treatment, a PET/CT (acquired AD) was registered to the planning CT (acquired AU) for arm delineation. The clinically delivered plan (AU) was recalculated with a density override to 1 g/cm for one or both arm contours (AD). Plans were also re-optimized for the AD position. Dose-volume parameters were compared for each scenario. Moving from AU to AD without re-optimization resulted in a mean 3.7% reduction in PTV D95; in all cases, this caused 95% of the PTV to receive ≤57 Gy. The mean arms D2cc were 23.1 and 4.0 Gy for the ipsilateral and contralateral, respectively. Dosimetric consequences of ipsilateral arm only were similar to both AD, whereas contralateral arm only had less than 1% effect on PTV D95. Re-optimizing to account for both AD recovered PTV D95 coverage with acceptable doses to all organs at risk. Arm D2cc were also decreased to 5.5 and 2.3 Gy for ipsilateral and contralateral, respectively. There was a significant difference in heart V25 and mean heart dose (P<0.001), but the magnitude was small at 4.1% for V25 and 1.7 Gy for mean heart dose and the plans still met institutional dose constraints. This planning study suggests that it is feasible to plan radiotherapy for locally advanced lung cancer patients in the AD position using VMAT, when necessary, with only a modest dosimetric impact.
根治性胸部放疗理想的体位是双臂上举(AU)位;然而,患者的舒适度可能仅允许双臂下垂(AD)位可行。本研究的目的是:(I)评估治疗期间改变手臂位置的剂量学影响;(II)比较在AU和AD位进行优化的计划质量。在这项回顾性计划研究中,确定了10例III期肺癌患者,他们采用容积调强弧形放疗(VMAT)接受30次分割共60 Gy的照射。为了模拟AD位治疗,将一次PET/CT(在AD位采集)与计划CT(在AU位采集)进行配准以勾画手臂轮廓。临床实施的计划(AU位)针对一个或两个手臂轮廓(AD位)采用密度覆盖1 g/cm³进行重新计算。计划也针对AD位进行重新优化。比较每种情况下的剂量体积参数。从AU位转换到AD位且不重新优化导致计划靶体积(PTV)D95平均降低3.7%;在所有病例中,这使得95%的PTV接受的剂量≤57 Gy。同侧和对侧手臂的平均D2cc分别为23.1 Gy和4.0 Gy。仅同侧手臂的剂量学后果与双侧AD位相似,而仅对侧手臂对PTV D95的影响小于1%。重新优化以考虑双侧AD位后,PTV D95覆盖得以恢复,且对所有危及器官的剂量均可接受。同侧和对侧手臂的D2cc也分别降至5.5 Gy和2.3 Gy。心脏V25和平均心脏剂量存在显著差异(P<0.001),但幅度较小,V25为4.1%,平均心脏剂量为1.7 Gy,但计划仍符合机构剂量限制。这项计划研究表明,必要时,对于局部晚期肺癌患者,采用VMAT在AD位进行放疗计划是可行的,且剂量学影响较小。